Orasi Medical company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

orasimedical.com

Total Raised

$7.66M

Investors Count

2

Deal Terms

2

Orasi Medical Funding, Orasi Medical Valuation & Orasi Medical Revenue

4 Fundings

Orasi Medical's latest funding round was a Dead for on February 7, 2012.

Orasi Medical's valuation in May 2009 was $15.49M.

Orasi Medical's latest post-money valuation is from May 2009.

Sign up for a free trial to see Orasi Medical's valuations in October 2007 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/7/2012

Dead

Dead

0

FY undefined

1

11/17/2010

Series C

$99M

0

FY undefined

0

5/6/2009

Series B

$99M

$15.49M

0

FY undefined

0

10/18/2007

Series A

$99M

$99M

0

FY undefined

0

Date

2/7/2012

11/17/2010

5/6/2009

10/18/2007

Round

Dead

Series C

Series B

Series A

Amount

$99M

$99M

$99M

Investors

Dead

Valuation

$15.49M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

0

0

0

Orasi Medical Deal Terms

2 Deal Terms

Orasi Medical's deal structure is available for 2 funding rounds, including their Series B from May 06, 2009.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Orasi Medical Investors

2 Investors

Orasi Medical has 2 investors. PrairieGold Venture Partners invested in Orasi Medical's Series C funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/18/2007

11/17/2010

3
Series B, Series A (2007), Series C (2010)

Venture Capital

South Dakota

00/00/0000

00/00/0000

CentreStone Ventures

Subscribe to see more

Venture Capital

Canada

First funding

10/18/2007

00/00/0000

Last Funding

11/17/2010

00/00/0000

Investor

CentreStone Ventures

Rounds

3
Series B, Series A (2007), Series C (2010)

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Location

South Dakota

Canada

You May Also Like

Alzeca Biosciences Logo
Alzeca Biosciences

Alzeca Biosciences develops imaging compounds to diagnose Alzheimer's disease at the earliest stages. Early detection of Alzheimer's is critical as disease pathology begins to accumulate 10+ years prior to cognitive onset of the disease. As a result, early detection of Alzheimer's pathology offers the patient an opportunity to take counteractive measures at a point where the disease may still be treatable.

N
NeuroVision Imaging

NeuroVision Imaging is developing retinal imaging technology for early detection and monitoring of Alzheimer's disease.

N
Neurotrack Technologies

Neurotrack is a digital medicine solution for Alzheimer's disease, giving people direct access to the scientifically validated digital diagnostic and therapeutic to delay or prevent memory health conditions.

Darmiyan Logo
Darmiyan

Darmiyan develops fully automated proprietary software that inputs human brain MRIs and produces maps that detect Alzheimer's disease up to fifteen years before symptoms. Its mission is to create a fast, non-invasive, inexpensive, precise, and globally accessible tool for brain health screening and monitoring. Darmiyan's technology provides a platform for presymptomatic diagnosis of neurodegenerative disorders, with precise quantification and localization of microscopic abnormality in the brain.

A
ADispell

ADispell is a pharmaceutical development company with technology related to Alzheimers, cognition-loss disease, drug addiction, and other CNS areas. Three lead compounds have been identified for this platform technology and in vivo experiments have produce clear evidence of improved cognition and learning in impaired animals. Our team will continue pre-clinical work with the goal of licensing our development to a pharma partner. These deals have closed for $100s of millions of dollars.

Cytox Logo
Cytox

Cytox is developing a diagnostic test and therapeutic cures for Alzheimer's Disease. The company is a university spin-out based on academic research into the role of the cell cycle in neuro-degenerative diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.